Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
The use of imatinib mesylate (Gleevec), a selective tyrosine kinase inhibitor, has become the new gold standard for the treatment of chronic myeloid leukemia. Unfortunately, the medication has been commonly associated with mild to severe cutaneous reactions, which has limited its use for some patients. We describe a case of a successful progressive challenge of a patient with a drug-induced exanthem from imatinib mesylate and a review of the literature.
Park
Miguel A
MA
Division of Allergic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Volcheck
Gerald W
GW
Guarderas
Juan C
JC
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D003888:Desensitization, Immunologic; D003875:Drug Eruptions / Q000209:etiology / Q000628:therapy*; D005076:Exanthema / Q000139:chemically induced* / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate